Search research articles
Contact Us
Filters
Showing results (401-410 of 478) with videos related to
Page
of 48
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 26, 2020
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
Yuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, et al.
Plos One
|
December 16, 2014
Cautious application of pleural N-terminal pro-B-type natriuretic peptide in diagnosis of congestive heart failure pleural effusions among critically ill patients
Jiann-Horng Yeh, Chun-Ta Huang, Chia-Hsiung Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 8, 2017
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
Wen-Chi Yang, Furen Xiao, Jin-Yuan Shih, et al.
Cancer Medicine
|
August 29, 2023
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
Hye Ryun Kim, Shunichi Sugawara, Jong-Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2009
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
Tony S K Mok, Yi-Long Wu, Chong-Jen Yu, et al.
Shock (Augusta, Ga.)
|
January 21, 2025
INCREASED CIRCULATORY KREBS CYCLE METABOLITES IN SEPSIS IS ASSOCIATED WITH INCREASED INTERLEUKIN-6 RELEASE AND WORSE SURVIVAL
Kuei-Pin Chung, Yi-Hsuan Chen, Yi-Jung Chen, et al.
Cancer Medicine
|
December 23, 2023
Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer
Yen-Ting Lin, Chao-Chi Ho, Wei-Hsun Hsu, et al.
The Lancet. Respiratory Medicine
|
December 19, 2017
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Chia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma
Jin-Yuan Shih, Meng-Feng Tsai, Tzu-Hua Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 2, 2015
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok, Yi-Long Wu, Jin Soo Lee, et al.
Page
of 48
Search research articles
Search
Showing results (401-410 of 478) with videos related to
Sort By:
Page
of 48
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
February 26, 2020
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan
Yuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, et al.
Plos One
|
December 16, 2014
Cautious application of pleural N-terminal pro-B-type natriuretic peptide in diagnosis of congestive heart failure pleural effusions among critically ill patients
Jiann-Horng Yeh, Chun-Ta Huang, Chia-Hsiung Liu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 8, 2017
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
Wen-Chi Yang, Furen Xiao, Jin-Yuan Shih, et al.
Cancer Medicine
|
August 29, 2023
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
Hye Ryun Kim, Shunichi Sugawara, Jong-Seok Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2009
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
Tony S K Mok, Yi-Long Wu, Chong-Jen Yu, et al.
Shock (Augusta, Ga.)
|
January 21, 2025
INCREASED CIRCULATORY KREBS CYCLE METABOLITES IN SEPSIS IS ASSOCIATED WITH INCREASED INTERLEUKIN-6 RELEASE AND WORSE SURVIVAL
Kuei-Pin Chung, Yi-Hsuan Chen, Yi-Jung Chen, et al.
Cancer Medicine
|
December 23, 2023
Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer
Yen-Ting Lin, Chao-Chi Ho, Wei-Hsun Hsu, et al.
The Lancet. Respiratory Medicine
|
December 19, 2017
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Chia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma
Jin-Yuan Shih, Meng-Feng Tsai, Tzu-Hua Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 2, 2015
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok, Yi-Long Wu, Jin Soo Lee, et al.
Page
of 48